Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04374656 Completed - COVID-19 Clinical Trials

Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic

Start date: May 18, 2020
Phase:
Study type: Observational

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified, highly contagious RNA virus causing respiratory infectious disease, Coronavirus Disease 2019 (COVID-19). Conjunctivitis has been reported as a rare finding of the disease, and preliminary studies showed that the virus RNA could be detected in ocular secretions using polymerase chain reaction (PCR) assays when conjunctivitis present. This study aims to estimate the proportion of SARS-CoV-2 associated conjunctivitis among patients with suspected viral conjunctivitis presented to the ophthalmology clinics of Wilmer Eye Institute during the COVID-19 pandemic. The investigators also aim to identify whether SARS-CoV-2 associated conjunctivitis is an isolated finding or an early sign of COVID-19.

NCT ID: NCT04374617 Completed - COVID-19 Clinical Trials

Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19

Start date: April 1, 2020
Phase:
Study type: Observational

Severe COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.

NCT ID: NCT04374565 Completed - Pneumonia Clinical Trials

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

Start date: May 5, 2020
Phase: Phase 2
Study type: Interventional

This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A total of 29 eligible subjects will be enrolled to receive anti-SARS-CoV-2 plasma.Outcomes will be compared to hospitalized controls with confirmed COVID-19 disease through retrospective chart review.

NCT ID: NCT04374526 Completed - Clinical trials for Coronavirus Disease 2019 )COVID-19)

Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.

LIFESAVER
Start date: May 27, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Older age is an independent poor outcome predictor among COVID-19 hospitalized patients . Among 72,314 COVID-19 cases, case fatality rate (CFR) was 2.3% in total population, 8% in people aged 70 to 79, and 14.8% in those aged 80 and older. In the whole population, CFR was higher in people with comorbidities, ranging from 5-6% in persons with hypertension, chronic respiratory disease, diabetes or cancer, up to 10% in those with cardiovascular diseases. Sars-CoV-2 seems to be able to induce a functional exhaustion of specified T and NK lymphocyte subpopulations, breaking down antiviral immunity. One possible explanation is that the immune system of elderly people, might be exhausted by chronic stimulation associated with comorbidities and more susceptible to this Sars-CoV-2 effect. As a result, in these patients, the activation of the innate immune system might fail to produce an adequate adaptive response (i.e., virus-specific CD8+ T-cells). This results in persistent self-induced inflammation that eventually causes mortality. The investigators hypothesize that transfusing convalescent plasma (containing neutralizing antibodies) at an early phase of COVID-19 infection could prevent or switch off the persistent inflammatory response elicited by the virus. The objective of this study are: - To demonstrate the superiority of COVID-19 convalescent plasma (CCP) plus standard therapy (ST) over ST alone - To prevent progression of pneumonia in COVID-19 patients aged ≥65 with chronic comorbidities - To decrease viral load - To raise anti-SARS-CoV-2 antibody titer in recipients

NCT ID: NCT04374513 Completed - Covid19 Clinical Trials

Community Pharmacists Behaviour During Covid-19

Start date: April 2, 2020
Phase:
Study type: Observational

During the COVID-19 pandemic, governments issued movement restrictions and placed areas into quarantine to reduce the spread of the disease.Community pharmacists and their teams are a vital healthcare provider during the outbreak; they remain on the frontline of public health by serving as direct points of access for their patients. The retail pharmacists should provide public community, costumers and patients with right and trusted information about covid-19. They also should have role in awareness spreading regarding personnel safety and hygiene

NCT ID: NCT04374422 Completed - COVID Clinical Trials

COVID-19 Pandemic and Female Sexual Behavior

Start date: April 10, 2020
Phase:
Study type: Observational

World Health Organization declared new SARS-CoV-2 infection a pandemic, and many states enacted strict, rules such as border closures, transportation restrictions and quarantine.Many studies in the literature have described the relationship between mass disasters and female sexual behavior, but none have investigated the effect of SARS-CoV-2 pandemic on women's sexual attitude. The aim of this study is therefore to evaluate the effect of SARS-CoV-2 pandemic on female sexual behavior.

NCT ID: NCT04374149 Completed - COVID19 Clinical Trials

Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

Start date: April 30, 2020
Phase: Phase 2
Study type: Interventional

This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS). It is hypothesized that dual intervention of acute apheretic depletion of cytokines and concomitant suppression of production will produce superior amelioration of the cytokine load and to help to prevent cytokine load rebound. This protocol is envisioned as a pilot study (n=20) for hypothesis generation for future investigation.

NCT ID: NCT04374123 Completed - COVID Clinical Trials

COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit

Start date: April 20, 2020
Phase:
Study type: Observational

The novel COronaVIrus Disease 19 (COVID-19) outbreak has impacted daily activities in nearly 210 countries and territories worldwide. In Ecuador, the city of Guayaquil has nearly two-thirds of the COVID-positive patients in the country and nearly 40% of infected individuals are health-care related personnel. Nonemergent, emergent and urgent endoscopic procedures are necessary to be performed during the COVID-19 pandemic. Several experiences in the management of the endoscopic unit during the pandemic has been proposed. We aimed to prospectively evaluate a strict protocol for preventing potential nosocomial infection of COVID-19.

NCT ID: NCT04374071 Completed - COVID Clinical Trials

Early Short Course Corticosteroids in COVID-19

Start date: March 12, 2020
Phase:
Study type: Observational

The investigators intend to study the role of early use of methylprednisolone in the hospitalized patients with a diagnosis of COVID-19 pneumonia.

NCT ID: NCT04374032 Completed - COVID-19 Infection Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

Start date: May 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection